Activity of Opioid Ligands in Cells Expressing Cloned Mu Opioid Receptors

Overview

Journal BMC Pharmacol

Publisher Biomed Central

Specialty Pharmacology

Date 2003 Jan 7

PMID 12513698

Citations 30

Authors

Parham Gharagozlou

Hasan Demirci

J David Clark

Jelveh Lameh

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine.

Results: Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin.

Conclusion: These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.

Citing Articles

Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.

Barr G, Schmidt H, Thakrar A, Kranzler H, Liu R CNS Neurosci Ther. 2024; 30(9):e70034.

PMID: 39295098 PMC: 11410865. DOI: 10.1111/cns.70034.

Incidence and risk factors of postoperative nausea and vomiting in lung cancer patients following lobectomy and application of analgesic pumps.

Wu S, Gan C, Huang X, Jiang D, Xu Y, Liao Y J Int Med Res. 2022; 50(6):3000605221105343.

PMID: 35735025 PMC: 9235308. DOI: 10.1177/03000605221105343.

Dezocine as a potent analgesic: overview of its pharmacological characterization.

Ye R, Jiang S, Xu X, Lu Y, Wang Y, Liu J Acta Pharmacol Sin. 2021; 43(7):1646-1657.

PMID: 34737418 PMC: 9253008. DOI: 10.1038/s41401-021-00790-6.

Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.

Wu L, Dong Y, Zhu Q, Zhang B, Ai B, Yan T BMC Cancer. 2021; 21(1):1128.

PMID: 34670518 PMC: 8529774. DOI: 10.1186/s12885-021-08850-0.

In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.

Vandeputte M, Cannaert A, Stove C Arch Toxicol. 2020; 94(11):3819-3830.

PMID: 32734307 DOI: 10.1007/s00204-020-02855-7.

References

Keith D, Murray S, Zaki P, CHU P, Lissin D, Kang L . Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996; 271(32):19021-4. DOI: 10.1074/jbc.271.32.19021. View

Filizola M, Villar H, Loew G . Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J Comput Aided Mol Des. 2001; 15(4):297-307. DOI: 10.1023/a:1011187320095. View

Howes J, Bousquet A . Development of TR5379M (xorphanol mesylate), an oral analgesic. NIDA Res Monogr. 1983; 43:231-7. View

Kenakin T . Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2002; 42:349-79. DOI: 10.1146/annurev.pharmtox.42.091401.113012. View

Horan P, Ho I . Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol Biochem Behav. 1989; 34(4):847-54. DOI: 10.1016/0091-3057(89)90284-0. View

Segredo V, Burford N, Lameh J, Sadee W . A constitutively internalizing and recycling mutant of the mu-opioid receptor. J Neurochem. 1997; 68(6):2395-404. DOI: 10.1046/j.1471-4159.1997.68062395.x. View

Mantegazza P, Tammiso R, Zambotti F, Zecca L, ZONTA N . Purine involvement in morphine antinociception. Br J Pharmacol. 1984; 83(4):883-8. PMC: 1986980. DOI: 10.1111/j.1476-5381.1984.tb16527.x. View

Gades N, Danneman P, Wixson S, Tolley E . The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. Contemp Top Lab Anim Sci. 2001; 39(2):8-13. View

Lameh J, Eiger S, Sadee W . Interaction among mu-opioid receptors and alpha 2-adrenoceptors on SH-SY5Y human neuroblastoma cells. Eur J Pharmacol. 1992; 227(1):19-24. DOI: 10.1016/0922-4106(92)90137-k. View

10.

Wang J, Johnson P, Persico A, Hawkins A, Griffin C, Uhl G . Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994; 338(2):217-22. DOI: 10.1016/0014-5793(94)80368-4. View

11.

Suh H, SIM Y, Choi Y, Song D, Kim Y . Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin. Gen Pharmacol. 1995; 26(7):1597-602. DOI: 10.1016/0306-3623(95)00056-9. View

12.

Bot G, Blake A, Li S, Reisine T . Mutagenesis of a single amino acid in the rat mu-opioid receptor discriminates ligand binding. J Neurochem. 1998; 70(1):358-65. DOI: 10.1046/j.1471-4159.1998.70010358.x. View

13.

Abdelhamid E, Sultana M, Portoghese P, TAKEMORI A . Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther. 1991; 258(1):299-303. View

14.

Jones K, Barr G . Ontogeny of morphine withdrawal in the rat. Behav Neurosci. 1995; 109(6):1189-98. DOI: 10.1037//0735-7044.109.6.1189. View

15.

Yoshimura M, Wu P, Hoffman P, Tabakoff B . Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine. Mol Pharmacol. 2000; 58(5):1011-6. DOI: 10.1124/mol.58.5.1011. View

16.

Somrat C, Oranuch K, Ketchada U, Siriprapa S, Thipawan R . Optimal dose of nalbuphine for treatment of intrathecal-morphine induced pruritus after caesarean section. J Obstet Gynaecol Res. 1999; 25(3):209-13. DOI: 10.1111/j.1447-0756.1999.tb01149.x. View

17.

Lameh J, Wang P, Meredith D, Shafer S, Loew G . Characterization of benzodiazepine receptors in the cerebellum. Prog Neuropsychopharmacol Biol Psychiatry. 2000; 24(6):979-91. DOI: 10.1016/s0278-5846(00)00114-7. View

18.

Smart D, Smith G, Lambert D . Mu-opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium-channel opening. Biochem J. 1995; 305 ( Pt 2):577-81. PMC: 1136401. DOI: 10.1042/bj3050577. View

19.

Kjellberg F, Tramer M . Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001; 18(6):346-57. DOI: 10.1046/j.0265-0215.2000.00826.x. View

20.

Gharagozlou P, Demirci H, Clark J, Lameh J . Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. BMC Neurosci. 2002; 3:19. PMC: 137588. DOI: 10.1186/1471-2202-3-19. View